Test Price
2,400 AED✅ Home Collection Available
Thalassemia Beta Trio Prenatal Mutation Detection Test in UAE | AED 2,400 | 2026 DHA Guidelines
تحليل الكشف عن طفرات بيتا ثلاسيميا الثلاثي قبل الولادة في الإمارات | 2400 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
ملخص تنفيذي: دقة تشخيصية بنسبة 99.9% لفحص طفرات بيتا-ثلاسيميا للوالدين والجنين، معتمد من هيئة الصحة بدبي وفق القانون الاتحادي رقم 41 لسنة 2024.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified processing.
- Premium Logistics: Hospital‑Grade Home Collection (8 AM‑11 PM) with ISO‑Certified Cold‑Chain transport for both blood and amniotic fluid.
- Clinical Guidance: Complimentary telephonic post‑test clinical correlation session with a Haematologist/Geneticist.
- Insurance & Billing: Direct Billing Verification via WhatsApp +971 54 548 8731.
Overview
The Thalassemia Beta Trio Prenatal Mutation Detection test simultaneously analyses beta‑globin gene mutations in both biological parents and the unborn child using amniotic fluid DNA. This definitive molecular evaluation allows families to make informed reproductive decisions based on a 2026 DHA‑approved, 99.9%‑sensitive protocol.
| Feature | Our Trio Prenatal Test | Closest Alternative (Parental Carrier Screening Only) |
|---|---|---|
| Analytical Scope | Fetal + both parents (trio) – full beta‑globin gene sequencing | Only maternal/paternal carrier status; no fetal genotype |
| Methodology | PCR Amplification + Sanger Sequencing (gold standard) with optional NGS confirmation | PCR‑based common‑mutation panel (limited mutations) |
| Turnaround Time | 5 working days (Sample Mon by 11 AM → Report Fri) | 7–14 days |
| Clinical Actionability | Definitive fetal risk for β‑thalassaemia major/intermedia | Probability‑based, often requiring follow‑up invasive test |
Clinical Insight & Safety Protocol
“This trio prenatal test provides critical genetic clarity for families at risk for beta‑thalassaemia. While its 99.9% sensitivity is exceptionally high, results must be interpreted alongside ultrasound findings and thorough genetic counselling. Confirmatory invasive testing and multidisciplinary consultation are essential before any life‑altering decision.”
— Dr. Prabhakar Reddy, Haematology Specialist (DHA License: 61713011)
Important Medication Warning
Do not discontinue any prescribed medication without explicit instruction from your treating physician.
Safety Exclusion Criteria & Emergency Red Flags
- Test Exclusion: Inability to provide informed consent; incomplete mandatory forms (Form 18 & Form 20); maternal age <18 years; active vaginal bleeding, ruptured membranes, or known coagulopathy contraindicating amniocentesis; sample shipped frozen or without cold‑chain integrity.
- Seek Immediate Emergency Care If: Severe abdominal pain, fever >38°C, persistent leakage of amniotic fluid, heavy vaginal bleeding, or signs of infection (chills, foul‑smelling discharge) after the amniocentesis procedure.
Frequently Asked Questions
What is the Thalassemia Beta Trio Prenatal Mutation Detection Test?
This test simultaneously analyses beta‑globin gene mutations in both parents and the fetus using amniotic fluid DNA for accurate prenatal risk assessment. It screens for over 200 known Mediterranean and Asian mutations through PCR amplification and Sanger sequencing. The trio design compares fetal genotype with parental carrier status, allowing detection of de novo or inherited pathogenic variants associated with beta‑thalassaemia major, intermedia, and silent carrier states. All procedures comply with DHA’s 2026 prenatal genetic testing framework, Federal Decree-Law No. 41 of 2024, and the CDS Law for minors, ensuring complete ethical and legal adherence.
يقوم هذا الفحص بتحليل طفرات جين بيتا-غلوبين لدى الوالدين والجنين عبر عينة السائل الأمنيوسي للتنبؤ بحالات الثلاسيميا الشديدة. تمتثل جميع الإجراءات لقانون الخدمات الرقمية للقُصّر 2026 والقانون الاتحادي رقم 41 لسنة 2024.
How accurate is this prenatal test for beta‑thalassaemia?
With 99.9% diagnostic sensitivity, our trio test reliably detects over 95% of common beta‑globin mutations found in UAE's high‑risk populations. The method targets point mutations, small deletions, and insertions across the HBB gene. Analytical specificity exceeds 99.8%. For rare variants, supplementary NGS confirmation is included at no extra cost. Results are validated against ISO 9001:2015 standards (Cert: INT/EGQ/2509DA/3139) and every report is reviewed by a DHA‑licensed haematologist before release.
بدقة تشخيصية تصل إلى 99.9%، يكتشف أكثر من 95% من طفرات بيتا-غلوبين الشائعة في سكان الإمارات عاليي الخطورة. يتم تأكيد الطفرات النادرة بتقنية التسلسل الجيني من الجيل التالي مجاناً.
What are the sample requirements, pre‑test preparation, and turnaround time?
Both parents provide 4 mL EDTA whole blood each, plus 10 mL of amniotic fluid collected by your obstetrician; results are delivered in 5 working days. Ship all samples refrigerated (2‑8°C); DO NOT FREEZE. Mandatory forms include the Prenatal Genetic Testing Consent Form (Form 18) and Genomics Clinical Information Requisition (Form 20). A DHA‑regulated home collection service is available daily from 8 AM to 11 PM for both blood and amniotic fluid, with strict cold‑chain maintenance and immediate transfer to our ISO‑certified laboratory. Final reports include carrier status for each parent and fetal genotype, along with a clinical interpretation.
يقدم كل من الوالدين 4 مل من الدم في أنبوب EDTA، و10 مل من السائل الأمنيوسي؛ والنتائج خلال 5 أيام. الشحن مبرد ويمنع التجميد. النماذج الإلزامية: نموذج الموافقة على الفحص الجيني قبل الولادة (18) ونموذج المعلومات السريرية للجينوم (20).
UAE Regulatory Compliance & Data Stewardship
provided under DHA/MOHAP Facility License 9834453. Personal health data is processed in full compliance with UAE Federal Decree‑Law No. 41 of 2024 (Art. 87), the Minors’ Digital Services Law 2026, and UAE PDPL data privacy statutes. All genetic counselling sessions and results are governed by ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
Assigned 2026 ICD‑10‑CM codes: D56.1 (Beta thalassaemia), O35.8XX0 (Maternal care for suspected fetal hereditary disease), Z31.430 (Encounter for genetic testing of female for procreative management). LOINC: 21698‑3 (Beta globin gene [Presence] in Amniotic fluid by Molecular genetics method).
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians